Drug combo aims to halt lung scarring in scleroderma
NCT ID NCT06549231
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo infusions plus MMF. The main goal is to measure changes in forced vital capacity (a key lung function test) after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab and mycophenolate mofetil
- What this could lead to
- If it works, this combination could slow or stop lung damage in people with severe systemic sclerosis-related lung disease.
- What could go wrong
- This is a phase 3 trial, but the sample size is modest (102 people). The drugs may cause side effects like infections, and the benefit may not be large enough to change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE WITH SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Tours
RECRUITINGTours, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.